Real-world study of Sotyktu for psoriasis in Korea
Treatments studied
Part of Skin clinical trials.
This study looks at how safe and effective a pill called Sotyktu is for people with moderate-to-severe plaque psoriasis in real-life medical settings in Korea. If you are 19 or older and are about to start Sotyktu for your psoriasis as your doctor prescribes, this study may be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You have moderate-to-severe plaque psoriasis (red, thick, scaly patches on your skin).
- Your doctor has said you could benefit from light therapy or medicines that work throughout your body.
- You are about to start taking Sotyktu as approved by Korean health authorities.
- You are not taking Sotyktu for a condition that is not approved in Korea.
- You have no health conditions that would make Sotyktu unsafe for you (as listed in the Korean prescribing info).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
This Phase 4 study tests whether deucravacitinib can improve psoriasis by correcting abnormal immune-cell signals seen in people with moderate-to-severe disease. It may help reduce symptoms and improve control of psoriasis, while researchers also track immune changes.
Hear when a new Moderate to Severe Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.